We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Randomized trial evaluates rituximab for new-onset generalized myasthenia gravis, highlighting targeted B-cell depletion as a viable early intervention.
ClinicalTrials.gov Identifier: NCT02950155.
No takes yet. Share an insight, caveat, or question.
Piehl et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: